High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas
Sign Up to like & getrecommendations! Published in 2024 at "Bone Marrow Transplantation"
DOI: 10.1038/s41409-024-02394-0
Abstract: Refractory aggressive lymphomas can be treated with allo-SCT, pursuing a graft-vs-lymphoma effect. While reduced intensity conditioning is safe, tumors often progress rapidly, indicating the need for more active conditioning regimens. The preclinical synergy we saw… read more here.
Keywords: aggressive lymphomas; myeloablative regimen; lymphomas; gem clo ... See more keywords
Cytoplasmic location of NR4A1 in aggressive lymphomas is associated with a favourable cancer specific survival
Sign Up to like & getrecommendations! Published in 2018 at "Scientific Reports"
DOI: 10.1038/s41598-018-32972-4
Abstract: The nuclear orphan receptor NR4A1 functions as tumour suppressor in aggressive lymphomas by pro-apoptotic genomic and non-genomic effects. Here, we immunohistochemically studied the clinico-pathological relevance of NR4A1 protein expression patterns in a cohort of 60… read more here.
Keywords: associated favourable; cytoplasmic nr4a1; aggressive lymphomas; favourable cancer ... See more keywords